FDA Rips 'Troubling' Drug Promo In Repeat Warning Letter

By Jeff Overley (November 21, 2013, 4:16 PM EST) -- For the second time in three years, Kadmon Pharmaceuticals LLC has sent promotional literature with faulty information on safety and effectiveness, a "particularly troubling" repeat offense, the U.S. Food and Drug Administration said in a warning letter released Wednesday....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!